Cancer Genetic Testing Insurance Denied? How to Appeal BRCA, Lynch Syndrome, and More

Cancer genetic testing — including BRCA1/2 hereditary testing, Lynch syndrome (mismatch repair gene) panels, hereditary breast and ovarian cancer panels, and companion diagnostic tests such as EGFR, ALK, KRAS, PD-L1, MSI-H, and TMB — is frequently denied by insurers despite its established clinical value and direct impact on treatment decisions. These denials are often overturned on appeal when the right clinical documentation and legal citations are presented.

Why Insurers Deny Cancer Genetic Testing

Genetic testing denials follow well-recognized patterns. Understanding which applies to your situation shapes your appeal strategy.

• "Not medically necessary": The insurer's utilization reviewer determined that genetic testing does not meet internal clinical criteria for your situation — often conflicting with NCCN guideline recommendations and your physician's clinical assessment.
• "Experimental or investigational": Some genetic tests are denied as unproven even when they have FDA approval as companion diagnostics or are recommended by NCCN guidelines. FDA-approved companion diagnostics such as the FoundationOne CDx panel cannot lawfully be denied as experimental.
• "Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization required but not obtained": Many cancer genetic testing services require pre-approval. A procedural denial does not eliminate the underlying clinical necessity.
• "Genetic counseling referral not completed": Some plans require documented genetic counseling before approving hereditary cancer syndrome testing such as BRCA1/2 panels.
• "Documentation insufficient": Clinical records do not adequately support the clinical indication — the test may be appropriate but the paperwork does not satisfy the insurer's specific criteria.
• "Step therapy or alternative not exhausted": For companion diagnostics, this denial is clinically irrational — without the test result, your oncologist cannot determine which targeted therapy is appropriate for your cancer.

How to Appeal a Cancer Genetic Testing Denial

Step 1: Identify the Denial Basis and Request the Clinical Policy Bulletin

Read your denial letter carefully and identify the exact reason code and the clinical criteria the insurer applied. Request the complete claims file including the insurer's clinical policy bulletin for genetic testing. Comparing the insurer's criteria against published NCCN guidelines is the foundation of your appeal.

Step 2: Obtain Your Oncologist's or Genetic Counselor's Detailed Letter

For cancer genetic testing appeals, the physician's letter is the most critical piece of evidence. The letter must include: the specific test requested with proper CPT code; the clinical indication based on diagnosis, family history, and why testing meets NCCN criteria for your situation; for companion diagnostics, an explicit statement that the test is required to determine appropriate treatment; the specific NCCN guideline version and section recommending this test; and a direct response to the insurer's stated denial reason. For BRCA1/2 testing, the USPSTF Grade B recommendation for BRCA-related risk assessment (under ACA Section 2713) may require coverage without cost-sharing for women with increased hereditary risk.

Step 3: Cite NCCN Guidelines and FDA Approval

NCCN Clinical Practice Guidelines provide specific criteria for when hereditary cancer genetic testing and companion diagnostics are recommended. NCCN Category 1 recommendations carry the highest evidence level. For companion diagnostics with FDA approval — such as the 22C3 IHC assay for PD-L1 or FoundationOne CDx for multiple biomarkers — include the FDA approval documentation. An insurer denying an FDA-approved companion diagnostic as experimental is taking a legally indefensible position.

Step 4: Address Companion Diagnostic Denials Specifically

For patients seeking immunotherapy coverage, PD-L1 testing denial creates a clinical catch-22: approval for pembrolizumab (Keytruda) requires a PD-L1 score that cannot be obtained without the test. Your appeal argument: "PD-L1 IHC testing using the 22C3 assay is an FDA-required companion diagnostic for pembrolizumab in [cancer type]. Without this test result, the appropriate treatment cannot be determined. Denial of this companion diagnostic effectively denies the patient access to FDA-approved, NCCN Category 1-recommended treatment." For MSI-H/dMMR and TMB-H testing, note Keytruda's tumor-agnostic FDA approvals — these biomarkers unlock coverage arguments across solid tumor types.

Step 5: Submit the Internal Appeal and Escalate if Needed

Send your appeal via certified mail and through the insurer's portal. Include all supporting documentation. If the internal appeal fails, request External Independent Review: Complete Guide" class="auto-link">external review by an oncology-specialized reviewer. File a complaint with your state's Department of Insurance, particularly if your state has specific cancer genetic testing mandates. External reviews overturn genetic testing denials in 40–60% of cases.

What to Include in Your Appeal

• Denial letter with reason codes and specific policy provision citations
• Oncologist's or genetic counselor's letter of medical necessity with NCCN guideline citations and CPT/ICD-10 codes
• NCCN guideline excerpt recommending the specific test for your cancer type and clinical situation
• FDA companion diagnostic approval documentation (for companion diagnostic disputes)
• Family history documentation relevant to hereditary cancer syndrome testing
• Medical records confirming your diagnosis, staging, and molecular profile
• USPSTF recommendation citation for preventive genetic testing (for hereditary risk screening)
• Insurer's clinical policy bulletin and a documented analysis of where it diverges from NCCN standards

Fight Back With ClaimBack

Cancer genetic testing denials require appeals that combine NCCN guideline citations, FDA companion diagnostic approval documentation, and specific clinical necessity arguments for your case. A generic appeal letter is easily denied. ClaimBack generates a professional, targeted appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal